Lev Pharmaceuticals to Present at C.E. Unterberg, Towbin Life Sciences Conference on Monday, October 30th.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : LEVP) announced today that Joshua Schein, Ph.D., Lev's Chief Executive Officer, will present at the C.E. Unterberg, Towbin Life Sciences Conference on Monday, October 30th, 2006 at 8:30 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy at The New York Palace
About Lev Pharmaceuticals, Inc. Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's product candidates are based on C1-esterase inhibitor ("C1-INH"), a human plasma protein plasma protein n. Any of the various dissolved proteins of blood plasma, including antibodies and blood-clotting proteins, that act by holding fluid in blood vessels by osmosis. that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. The Company is conducting a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of its lead product candidate, C1-INH for the acute and prophylactic treatment prophylactic treatment n. The institution of measures to protect a person from a disease to which he or she has been, or may be, exposed. Also called preventive treatment. of hereditary angioedema. Lev is also developing C1-INH for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role. Legal notice to investors: Certain matters discussed in this news release are "forward-looking statements." These forward-looking statements, which apply only on the date of this release, generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "estimates," "anticipates," "believes," "continues" or words of similar import. Similarly, statements that describe Lev's future plans, objectives or goals are also forward-looking statements, which generally involve known and unknown risks, uncertainties and other facts that may cause the actual results, performance or achievements of Lev to be materially different from those expressed or implied by such forward-looking statements. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other governmental regulation, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies. These statements are based on our current beliefs and expectations as to such future outcomes and Lev disclaims any obligation to update the forward-looking statements made herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion